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Abstract
By breeding TRAMP mice with S100A9 knock-out (S100A9
2/2) animals and scoring the appearance of palpable tumors we
observed a delayed tumor growth in animals devoid of S100A9 expression. CD11b
+ S100A9 expressing cells were not
observed in normal prostate tissue from control C57BL/6 mice but were readily detected in TRAMP prostate tumors. Also,
S100A9 expression was observed in association with CD68
+ macrophages in biopsies from human prostate tumors. Delayed
growth of TRAMP tumors was also observed in mice lacking the S100A9 ligand TLR4. In the EL-4 lymphoma model tumor
growth inhibition was observed in S100A9
2/2 and TLR4
2/2, but not in RAGE
2/2 animals lacking an alternative S100A9
receptor. When expression of immune-regulating genes was analyzed using RT-PCR the only common change observed in
mice lacking S100A9 and TLR4 was a down-regulation of TGFb expression in splenic CD11b
+ cells. Lastly, treatment of mice
with a small molecule (ABR-215050) that inhibits S100A9 binding to TLR4 inhibited EL4 tumor growth. Thus, S100A9 and
TLR4 appear to be involved in promoting tumor growth in two different tumor models and pharmacological inhibition of
S100A9-TLR4 interactions is a novel and promising target for anti-tumor therapies.
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Introduction
The TRAMP prostate cancer model is an established
spontaneous model of prostate cancer in immune competent
mice. The mechanistic basis behind the model is a transgenic
construct where the SV40 large antigen is expressed under control
of the probasin promoter [1]. Some variations in the time of tumor
incidence have been reported and appear to vary with the genetic
background of the animals [2], but most animals develop a tumor
before week 30. In addition, the TRAMP model has been used to
study metastasis and changes in the immune function of animals at
different stages of tumor development [3,4].
MDSCs are a heterogeneous population of cells (reviewed in
[5,6],[7]) characterized by the expression of CD11b and Gr-1 in
the mouse [8] [9]. These cells are strongly immuno-suppressive
and can be found in virtually all models of solid tumors and
functionally similar cells may accumulate during autoimmune
conditions and chronic inflammation (reviewed in [10]. In cancer,
solid tumors produce various soluble factors such as VEGF, GM-
CSF, M-CSF, IL-10 and TGFb as well as certain inflammatory
cytokines IL-6 and IL-1b that are involved in inducing the
development of MDSC (reviewed in [6,8,9]). The suppressive Gr-
1
+ CD11b
+ cell population has been sub-divided into two
functional subsets, Ly6G
+ CD11b
+ granulocytic MDSC and
Ly6C
hi CD11b
+ monocytic MDSC, respectively [11,12]. Thus,
the granulocytic MDSC were shown to suppress the T cell
response mainly through the production of reactive oxygen species
(ROS), while the monocytic MDSCs exerted suppression through
elevated activity of the iNOS and Arginase I enzymes. Other
investigators have defined functional sub-populations of MDSC
based on their surface expression level of the Gr-1 molecule
[13,14]. Also using this strategy, functionally similar granulocytic
and monocytic sub-populations could be defined.
In addition to the immunosuppression mediated by MDSCs,
the immunosuppressive cytokine TGFb is overexpressed by
tumors and has multiple functions in development of cancer
(Reviewed in [15,16]. Thus, it operates not only at the level of the
cancer cell but also influences tumor stroma, including the
attraction of MDSCs. TGFb is also a potent regulator of the
adaptive immune response and is involved both in effector T cell
polarization and in the effector function of regulatory T cells [17–
19]. Further, TGFb signaling has been shown to block the effector
T cell response to certain tumor cells [20,21]. Thus, blockade of
TGFb activity modulates the suppressive milieu generated by the
tumor such that the adaptive anti-tumor immune response
mediated CD8 T cell anti-tumor responses will be unleashed
[22–24].
The S100A9 protein belongs to the S100 protein family [25]. It
is a calcium-binding protein that is expressed primarily in
neutrophil granulocytes and in some monocyte subsets [26]. It
has recently been shown that in the presence of zinc S100A9
undergoes a conformational change and becomes a ligand for the
pro-inflammatory receptors Receptor for Advanced Glycation
End products (RAGE) and Toll like receptor 4 (TLR4) [27,28].
S100A9 is mostly expressed as a heterodimer together with
S100A8, another member of the S100 protein family [26].
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with inflammatory disease [29], but also in patients with prostate
cancer [30]. S100A9 can also be expressed on the cell surface of
immature monocytes [31], but its biological function as a cell
surface protein is largely unknown. A S100A9-binding small
molecule (ABR-215050) is presently in a Phase III clinical trial for
the treatment of prostate cancer [32] [33].
S100A9 has been shown to be involved in the development of
malignant disease. An increased expression of S100A9 can be
detected in the pre-metastatic lung at sites where immature
myeloid cells subsequently will be deposited [34]. Also, in colitis-
induced colon cancer an increased expression of S100A8/A9 as
well as RAGE has been reported [35]. Importantly, S100A9
expression has also been shown to be involved in MDSC function.
Further, in the EL4 lymphoma model reduced tumor growth was
observed in S100A9
2/2 animals compared to wildtype controls
[36]. This coincided with the reduction of the number of MDSC
in S100A9
2/2 animals. Also TLR4 has been shown to be involved
in tumor progression [37,38] in different tumor models. Thus,
both S100A9 and its receptor TLR4 may be involved in tumor
development.
We here report our findings concerning the role of S100A9 and
TLR4 expression using the spontaneous prostate cancer model
TRAMP, as well as the transplanted, syngeneic EL4 lymphoma
model.
Results
TRAMP mice on S100A9
2/2 genetic background have a
delay in tumor growth
As mentioned above, S100A9 has been shown to be important
for MDSC function and growth of the EL4 lymphoma in C57BL/
6 mice [36]. We wanted to address whether S100A9 expression
could influence the growth of a solid cancer in a spontaneous
prostate cancer model [1]. To this end, we back-crossed
S100A9
2/2 mice for 10 generations onto C57BL/6 mice and
subsequently crossed them with TRAMP mice on the same genetic
background. The animals were followed by palpation once weekly
from 10 weeks of age. Animals with a palpable tumor were
sacrificed and the presence of a prostate tumor confirmed by
necropsy. Figure 1 shows the time to palpable tumor for C57BL/6
TRAMP mice in grey (n=42) and the TRAMP S100A9
2/2
animals (n=34) in black. The median time to palpable tumor
(MT) was increased in TRAMP S100A9
2/2 animals from 26 to
29 weeks (p=0.0008; Gehan-Breslow-Wilcoxon test). We con-
cluded from these data that the absence of S100A9 expression
delays TRAMP tumor growth.
S100A9 expression in TRAMP animals and human
prostate cancer
Having established that S100A9 expression had an impact on
tumor growth we proceeded to perform an immunoflourescence
analysis of tumors from TRAMP mice. We first stained normal
prostate from C57BL/6 animals and TRAMP tumors for S100A9
expression. As shown in Figure 2A, normal prostate tissue from
C57BL/6 mice showed no S100A9 expression. In contrast,
TRAMP tumors in C57BL/6 mice showed focal expression of
S100A9 (Figure 2B). As a control, TRAMP tumors from
S100A9
2/2 animals showed no S100A9 expression (Figure 2C),
indicating that our staining was specific and that tumors from
TRAMP mice do not express S100A9. Lastly, co-staining with an
anti-CD11b reagent revealed that in nearly all of the S100A9
expressing foci we could observe a centrally positioned, CD11b
+
cell (Figure 2B). We conclude from these results that S100A9
production is induced in TRAMP tumors, and that the most likely
primary source of the protein are CD11b
+ cells and not tumor
cells.
We next wanted to verify that S100A9 expression could also be
detected in human prostate cancers. For this purpose we stained
samples from benign and tumor tissue in a tissue micro array
(TMA) containing 16 men with prostate cancer. As shown in
Figure 2D, also in human prostate tumors there was S100A9
expression which coincided with infiltrating macrophage-like
inflammatory cells in the tumor stroma. Occasionally focal
staining was also observed in tumor epithelial cells (data not
shown). The number of S100A9 stained inflammatory cells was
higher in tumors than in the surrounding non-malignant prostate
tissue. Some tumors contained many S100A9 positive immune
cells whereas the number was low in others. There was no obvious
relation between the number of S100A9 stained immune cells and
tumor Gleason score. The number of S100A9 positive cells in the
tumor stroma correlated to the number of tumor infiltrating CD68
positive macrophages (Figure 2E). We conclude from these
preliminary data that S100A9 expression is up-regulated in
prostate cancer tissue compared to adjacent normal prostate and
that this expression seems to correlate with infiltrating macro-
phage-like cells.
TRAMP mice on TLR4
2/2 genetic background have a
delay in tumor growth
S100A9 has been shown to be an endogenous TLR4 ligand
[27]. Furthermore, TLR4 has been shown to be involved in tumor
progression [37,38], and we therefore wanted to investigate
whether TLR4 expression could also influence tumor growth in
the TRAMP tumor model. To this end, TRAMP animals were
back-crossed with TLR4
2/2 mice and monitored for progression
to palpable tumor as above. The result showed that the MT in the
control mice in this experiment was 26 weeks, while in TLR4
2/2
mice MT was extended to 31 weeks (Figure 3A; p,0.0001).
Although the TRAMP model is an established and well-studied
tumor model it had limitations for our continued studies. It being a
Figure 1. TRAMP tumor growth is delayed in S100A9
2/2 mice.
Time to palpable tumor curves for C57BL/6 TRAMP mice (grey line;
n=42) and TRAMP S100A9
2/2 mice (black line; n=34). The median
time to palpable tumor (TM) was 26 and 29 weeks, respectively
(p=0.0008; Gehan-Breslow-Wilcoxon).
doi:10.1371/journal.pone.0034207.g001
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animals to perform properly controlled experiments. Also,
extraction of various tumor cell populations is, in our hands, very
inefficient. It has been shown by others that tumor growth is
delayed in S100A9
2/2 mice also in the EL4 lymphoma model
[36]. Therefore, we next investigated whether EL4 lymphoma
growth was also influenced by TLR4 expression. As shown in
Figure 3B, this was indeed the case. The tumor weight at 14 days
after inoculation, was significantly reduced in TLR4
2/2 animals.
We also observed a significant reduction of tumor weight in
S100A9
2/2 animals, as previously published (17) (Figure 3B).
Thus, we decided to continue our studies on the effect of S100A9
and TLR4 on tumor growth in the EL4 tumor system.
We then extended our studies using the EL4 lymphoma model
to involve another receptor that has been shown to have S100A9
as a ligand; RAGE [27]. RAGE has primarily been studied as a
pro-inflammatory receptor but has also been shown to be involved
in tumor progression [39]. We therefore investigated whether
growth of EL4 lymphoma cells were compromised in RAGE
2/2
animals. Figure 3B shows that the EL4 lymphoma tumor growth
was similar in RAGE
2/2 animals compared to controls 14 days
after inoculation. We conclude from these experiments that the
inhibition of tumor growth observed in the S100A9
2/2 mice
might be dependent on interactions between S100A9 and TLR4
while RAGE may have no dominant role in this tumor model.
CD11b
+ cell subpopulations in S100A9
2/2 and TLR4
2/2
animals
S100A9 has been shown to be expressed in immature myeloid
cells [31] and this cellular compartment has been shown to be
functionally compromised in S100A9
2/2 animals [36]. We
therefore investigated whether the absence of S100A9 and
TLR4 expression had any impact on the CD11b
+ cell subpopu-
lations. To this end, age matched C57BL/6 mice, TLR4
2/2,
S100A9
2/2 and RAGE
2/2 animals were inoculated with EL4
cells subcutaneously. Two weeks later the CD11b
+ cells in spleen
were stained for their Ly6C and Ly6G expression and analyzed by
FACS (Figure 4A). The ratio of CD11b
+Ly6G
+Ly6C
+/
CD11b
+Ly6C
++ cells was significantly reduced in TLR4
2/2
animals compared to C57BL/6 control animals (Figure 4B). In
animals inoculated with EL4 tumors the CD11b
+Ly6G
+Ly6C
+/
CD11b
+Ly6C
++ ratio was increased in all three mouse strains, but
was still significantly lower in TLR4
2/2 animals than in C57BL/6
controls (Figure 4B). We have also made the analysis looking at
absolute cell numbers rather than percentages which revealed that
the CD11b ratio of Ly6G
+ granulocytic population is reduced
relative to the Ly6C
+ monocytic population, without significantly
reducing the total number of CD11b
+ cells (data not shown). We
therefore conclude from these experiments that the relative
composition of splenic CD11b
+ cells with regard to the Ly6G
and Ly6C markers is altered in mice lacking either S100A9 or
TLR4 without changing the total number of CD11b
+ cells.
TGFb expression is down-regulated in S100A9
2/2 and
TLR4
2/2 animals
We next investigated the expression of immune regulating genes
by RT-PCR in CD11b
+ cells from the spleen of animals with and
without EL4 tumors. In addition, we performed this experiment in
parallel in C57BL/6, TLR4
2/2 and S100A9
2/2 animals. The
rational for this approach was that critical mediators should show
the same deviation in TLR4
2/2 and S100A9
2/2 animals
compared to C57BL/6 controls if they could be involved in the
observed in vivo effect on tumor growth regulation. When the RNA
expression of arginase I, IFNc, RAGE and iNOS were
investigated no such co-variation was observed (Figure S1).
However, TGFb RNA expression was significantly higher in
splenic CD11b
+ cells from naive C57BL/6 animals compared to
S100A9
2/2 and TLR4
2/2 mice. This difference was found in
control as well as in EL4 tumor bearing mice (Figure 5A).
To validate the observed effect on TGFb RNA expression we
next measured TGFb protein levels in serum from C57BL/6,
TLR4
2/2, S100A9
2/2 and RAGE
2/2 animals. As shown in
Figure 5B, the serum level in healthy animals were similar in all
four mouse strains. After inoculation with EL4 lymphoma cells the
expression level of TGFb was increased in C57BL/6 and
RAGE
2/2, but not in S100A9
2/2 or TLR4
2/2 animals. Thus,
the reduced tumor growth observed in S100A9
2/2 and TLR4
2/2
animals correlate with low TGFb RNA expression in splenic
CD11b
+ cells. Furthermore, TGFb systemic protein expression is
not induced after inoculation with tumor cells in these mouse
strains compared to controls. EL4 lymphoma cells expressed only
Figure 2. Monocytes/macrophages are the main S100A9
producing cells in TRAMP prostate and human prostate
tumors. IHC analysis of prostate sections from C57BL/6 mice, TRAMP
prostate tumors and TRAMP prostate tumors in S100A9
2/2 mice (A–C).
A representative section from one out of 5 analysed is shown. A. Left:
Anti-S100A9 (green), anti-CD11b (purple) and Hoechst (blue) from
C57BL/6 prostate tissue. Right: A merged image. Magnification 620. B.
Left: Anti-S100A9 (green), anti-CD11b (purple) and Hoechst (blue) from
a TRAMP tumor in C57BL/6 mice. Right: A merged image. Magnification
620. C. Left: Anti-S100A9 (green), anti-CD11b (purple) and Hoechst
(blue) from a TRAMP tumor in C57BL/6 S100A9
2/2 mice. Right: A
merged image. Magnification 620. Scale bars in panel A–C equals
63 mm. IHC analysis of human prostate cancer. Numerous S100A9
positive cells are observed in the tumor stroma. E. Consecutive section
from the same tumor stained with an antibody against CD68 expressed
on tumor infiltrating monocytes/macrophages.
doi:10.1371/journal.pone.0034207.g002
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2/2 mice and EL4 lymphoma growth in both S100A9
2/2 and TLR4
2/2 animals. A.
Time to palpable tumor curves for C57BL/6 TRAMP mice (black line; n=18) and TRAMP TLR4
2/2 mice (dashed line; n=32). The median time to
palpable tumor (TM) was 26 and 31 weeks, respectively (p=,0.0001; Gehan-Breslow-Wilcoxon). B. Tumor weight of EL4 lymphoma tumors scored 14
days after subcutaneous inoculation in C57BL/6, S100A9
2/2, RAGE
2/2 and TLR4
2/2 animals. Statistical analysis using two-tailed t test *** p=0.0008; *
p=0.039.
doi:10.1371/journal.pone.0034207.g003
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induced in vivo (Figure S2).
Interruption of S100A9/TLR4 interaction in vivo inhibits
EL4 cell growth
It has been shown that compounds belonging to the quinoline-
3-carboxamide class will bind to S100A9 and inhibit the
interaction between S100A9 and TLR4 or RAGE [27]. One
compound (ABR-215050; tasquinimod) has entered phase III
clinical testing for the treatment of prostate cancer and has been
shown to have anti-tumor activity in animal tumor models [40,41].
The ABR-215050 compound inhibits in a dose dependent way the
interaction between S100A9 and TLR4/MD2 (Figure 6A) or
RAGE (Figure S3 [27]). To directly test whether the S100A9/
TLR4/RAGE interaction was important for EL4 tumor growth in
vivo we therefore treated EL4 inoculated animals with 30 mg/kg
ABR-215050 and compared to control animals. As shown in
Figure 6B, this treatment significantly reduced EL4 tumor growth.
In addition, when the experiment was repeated and the serum
levels of TGFb in serum was analysed in control and ABR-215050
treated animals, a significant reduction of TGFb expression upon
Figure 4. The CD11b
+Ly6G
+Ly6C
+ cell population is reduced in spleens from S100A9
2/2 and TLR4
2/2 animals. FACS analysis of spleen
cells from C57BL/6, S100A9
2/2, TLR4
2/2 and RAGE
2/2 animals. Panel A: Left: The gate used for defining CD11b
+ cells is shown. Right: The Ly6C/Ly6G
populations used for comparison and defined as indicated. Panel B: The ratio of CD11b
+Ly6G
+C
+/CD11b
+Ly6C
++ cells in the different mouse strains in
the presence and absence of subcutaneous EL4 tumor, as indicated. Statistical analysis using two-tailed t test ** p=0.0034.
doi:10.1371/journal.pone.0034207.g004
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2/2 and TLR4
2/2 animals. A. Quantitative real time RT-PCR analysis (see Materials and
Methods) of TGFb RNA expression from CD11b
+ cells (.90% pure by FACS analysis) from the spleen of C57BL/6, S100A9
2/2 and TLR4
2/2 animals in
the absence of, or 14 days after inoculation, with 50,000 EL4 lymphoma cells subcutaneously. The mean expression from 4 separate experiments is
shown where the expression in the C57BL/6 controls have been set to 1. B. ELISA measurements of TGFb serum levels of C57BL/6 (filled circles),
RAGE
2/2 (filled triangles), S100A9
2/2 (filled squares) and TLR4
2/2 (filled diamonds) in the absence of, or 14 days after inoculation (open symbols),
S100A9 and Tumor Growth
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results above from S100A9
2/2, TLR4
2/2 and RAGE
2/2
animals we conclude that a molecular interaction between
S100A9 and TLR4 appears to be stimulatory for tumor cell
growth in this experimental system, and that TGFb expression
may be a surrogate marker for S100A9/TLR4 interaction in vivo.
Discussion
We have shown here that the absence of S100A9 or TLR4
expression delays tumor incidence in a spontaneous prostate
cancer model. After the initiation of the current investigation,
Cheng et al. [36] published an elegant study where they showed
that S100A9
2/2 animals were protected from growth of
transplantable tumors (EL4 lymphoma). They also showed that
MDSC had an increased expression of the S100A9 protein.
Furthermore, over-expression of S100A9 or S100A8/A9, but
interestingly not S100A8, promoted tumor growth and MDSC
development in parallel. The difference between the TRAMP
model studied here and a transplantable tumor is that the tumors
develop during a long time, typically .20 weeks, in a fully
immune competent host. This means that the immune system has
ample time to adapt to the signals released by a tumor. Thus, in
the present investigation, in contrast to that of Cheng et al. [36], all
the TRAMP/S100A9
2/2 animals developed palpable tumors,
although significantly later than the C57BL/6 control animals.
The same observation was true for TRAMP/TLR4
2/2 mice
while in contrast many TLR4
2/2 animals did not develop EL4
tumors. This observation could be explained by that although
S100A9
2/2, and possibly also TLR4
2/2 animals, may have a
compromised MDSC function, sufficient numbers of these cells
will with time accumulate and be able to down-regulate the
immune surveillance function of the host in the TRAMP model.
We also show here that TLR4 expression, like S100A9
expression [36], influences the growth of the EL4 lymphomas.
Hence, the effect of S100A9 and TLR4 on the growth of TRAMP
prostate tumors is also reflected in the growth of EL4 lymphoma.
Interestingly, while S100A9 has been shown to be a ligand both for
RAGE and TLR4 [27], no effect on EL4 lymphoma growth was
observed in RAGE
2/2 mice. Therefore, we suggest that it is
primarily the interaction between S100A9 and TLR4 that
promotes tumor growth in our studies.
To further strengthen that statement we also show that a small
molecule, ABR-215050, that inhibits the interaction between
S100A9 and TLR4 also inhibits EL4 lymphoma growth. ABR-
215050 has been shown to inhibit tumor growth in several models
of prostate cancer [40], partially explained by an anti-angiogenic
effect [41]. This molecule has been in clinical testing and shown
positive results in phase I and phase II clinical trials for the
treatment of castrate resistant, metastatic prostate cancer [32,33].
It is currently in phase III clinical development for the same
indication (see www.clinicaltrials.gov). Hence, our observations in
this experimental system might have a corollary in human disease
which would extend the implications of the role of S100A9
interactions in human disease.
S100A9 in tumors appeared to be primarily expressed by
CD11b
+ cells. In sections from human prostate cancer biopsies,
many immune cells in the stroma could be seen to express S100A9
and the number of CD68
+ macrophages correlated with the
number of S100A9
+ foci. Also, compared to normal prostate in
mice or adjacent normal prostate tissue in human biopsies,
S100A9 expression was found mostly in tumor tissue. With regard
to TLR4 we have been unable to detect any expression using
immuno flourescence, while we have observed occasional RAGE
expression in TRAMP tumors (data not shown). However, when
EL4 lymphoma growth was investigated using RAGE
2/2 mice we
could not detect any reduction of tumor cell growth. Since RAGE
has been shown to be important in tumor growth in other systems
[39], it is not far fetched to suggest that the effect of the S100A9/
RAGE interaction might be different than the S100A9/TLR4
interaction in the regulation of tumor growth.
Concerning the effects on MDSC we could detect that C57BL/
6 mice inoculated with EL4 tumors showed an increased ratio
between CD11b
+Ly6C
+G
+/Ly6C
++ cells in the spleen. In fact this
dominance in CD11b
+Ly6C
+G
+ MDSC was detected in several
different tumor models [12]. Interestingly, this ratio was lower in
S100A9
2/2 and TLR4
2/2 mice. In animals inoculated with EL4
tumors the CD11b
+Ly6C
+G
+/Ly6C
++ ratio was increased in all
mouse strains but remained lower in S100A9
2/2 and TLR4
2/2
mice. In RAGE
2/2 animals inoculated with EL4 tumors the
CD11b
+Ly6C
+G
+/Ly6C
++ ratio was even higher than in C57BL/
6 controls. Hence, the mouse strains that show a reduced growth
of EL4 lymphoma cells have a lower ratio of CD11b
+Ly6C
+G
+/
Ly6C
++ cells in the spleen. We therefore believe that the
CD11b
+Ly6C
+G
+ MDSC may be more important in promoting
tumor growth in this model. Interestingly, CD11b
+Ly6G
+ cells is
the subpopulation of CD11b
+ cells that express the highest level of
S100A9 (Figure S4). Thus, it can be speculated that these cells
release S100A9 that via interaction with TLR4 promote tumor
growth. Lastly, these data also indicate that S100A9, RAGE, or
TLR4 expression does not appear to be absolutely required for the
expansion of CD11b
+ cells.
When splenic CD11b
+ cells were analyzed for the expression of
immunomodulatory genes using RT-PCR, the only significant
difference detected in both S100A9
2/2 and TLR4
2/2 animals
compared to C57BL/6 controls, both in animals with or without
EL4 tumors, was TGFb RNA expression. When this analysis was
extended to TGFb expression at the protein level we found that
while TGFb serum levels in C57BL/6 and RAGE
2/2 mice
increased in tumor-inoculated animals it did not in S100A9
2/2
and TLR4
2/2 animals. However, unlike the RNA data TGFb
systemic levels were not reduced in S100A9
2/2 and TLR4
2/2
animals indicating that other cells than splenic CD11b
+ cells
contribute to the systemic level of TGFb. Also, when tumor
inoculated animals were treated with ABR-215050 the reduction
of tumor growth coincided with reduced serum TGFb levels. This
is most likely not due to the relative lower tumor burden since the
EL4 tumor used expressed only very low levels of TGFb both in
vitro and in vivo (Figure S2). TGFb plays multiple roles in cancer
and is also involved in regulating the adaptive immune response
both to tumors and infection (reviewed in [15–17,19]. We
therefore believe that the correlation between TGFb expression
and tumor development described in here may be of significance.
Whether the reduced production of TGFb mediates the observed
reduction in tumor growth, and whether the skewed ratio of
CD11b
+Ly6C
+G
+/Ly6C
++ cells is involved in the control of
TGFb levels, remains to be determined.
In conclusion, besides its involvement in the metastatic process
[34], S100A9 also appears to be involved in the growth control of
established tumors. The interference with S100A9 signaling may
with 50,000 EL4 lymphoma cells subcutaneously. Statistical analysis using two-tailed t test *** p=0.0008; * p=0.039 and 0.0028, respectively. There
was no statistical significant difference in TGFb serum levels between EL4 inoculated C57BL/6 or RAGE
2/2 mice.
doi:10.1371/journal.pone.0034207.g005
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malignant disease, for example in the prostate. Particularly as
human prostate tumors contain numerous S100A9 expressing
inflammatory cells and also some S100A9 expressing tumor
epithelial cells [30], and the overall effect of infiltrating monocytes
is to stimulate prostate tumor growth [42,43]. The result from
ongoing clinical trials with S100A9-binding compounds will add
further information concerning this possibility.
Materials and Methods
Animals
C57BL/6 mice, S100A9
2/2 [44], TLR4
2/2, RAGE
2/2 and
TRAMP [1] (Jackson Laboratories) mice were kept in an SPF
animal facility at BMC, Lund. Female C57Bl/6 TRAMP mice
heterozygous for the Probasin SV-40 Tag transgene were bred to
non-transgenic C57Bl/6 males (Taconic M&B, Ry, Denmark), as
well as to TLR4
2/2 and S100A9
2/2 on a C57BL/6 background.
Ear DNA was isolated from all mice, and transgenic animals were
identified via PCR based screening after each crossing. TRAMP
tumors were scored by blinded palpation and sacrificed upon
being palpation positive, according to local ethical guidelines.
Necropsy was performed on all animals and only animals that had
a macroscopically visible prostate tumor were scored as tumor
bearing in the data set presented.
Human prostate cancer samples
To stain human prostate tissue for S100A9 and CD68
(monocytes) as described below, we used tissue micro arrays
(TMA) constructed from paraffin blocks from 403 prostate cancer
patients as described earlier [45]. Each patient was represented by
up to 8 cores of tumor and up to 4 cores of adjacent non-
malignant tissue. TMA cores from 16 patients were stained and
analyzed.
Immunohistochemistry
Tissues analysed with immunohistology were embedded in
OCT compound (Tissue-TekH), and snap-frozen in liquid
nitrogen. Cryosections (5–6 mm) were prepared on microscope
slides, air dried and frozen at 220uC until staining procedures.
PFA fixed sections were incubated with blocking 1% BSA 10%
serum and FcRII/III blocker solution followed by Avidin/Biotin
Blocking kit (Vector Laboratories, Inc. Burlingame, CA, USA).
Thereafter the sections were incubated for 30 min at room
temperature with primary antibodies: Rabbit-anti-S100A9, or the
appropriate isotype controls (BD Pharmingen). Followed by
Donkey- anti- rabbit Alexa488 (Molecular Probes) and anti-mouse
CD11b-APC conjugate (eBioscience San Diego CA, USA). The
slides were mounted using ProLong Gold mounting media
(Invitrogen, Oregon, USA). Images were acquired with a Axiovert
200 M Zeiss microscope (Carl Zeiss, Inc.) connected to a ORCA-
ER CCD camera (Hamamatsu, Japan), and analysed with
Volocity software (Improvision), or AxioVision 4.0 software (Carl
Zeiss, Inc.).
Five micron thick paraffin sections from the TMAs were stained
for CD68 using an antibody from DAKO, Stockholm, Sweden
and for S100A9 using an antibody from Santa Cruz Biotechnol-
ogy, CA, USA as earlier described [42,46].
Flow cytometry
Flow cytometric analysis was performed on spleen cell
suspensions, as indicated. Primary Abs used were: anti-mouse
CD11b APC (eBioscience), Ly6G-FITC (BD Pharmingen) and
Ly6C biotin (BD Pharmingen). Biotinylated antibodies were
detected with streptavidin-QD605 (Invitrogen). Propidium iodide
was added to samples before acquisition. Data were acquired using
a FACSAria flow cytometer (BD Biosciences) and analyzed using
FlowJo software (Tree Star).
Surface Plasmon Resonance (SPR) analysis
Analysis of S100A9 binding to TLR4 was carried out on a
BIAcore 3000 System (GE Healthcare). Recombinant TLR4/
MD2 complex was immobilized on a CM5 sensor chip (GE
Healthcare) to a density of ,2,300 RU by coupling via primary
amines. S100A9, in the absence or presence of ABR-215050, was
injected (2 min at 30 mL/min) at 1.3 mg/mL (50 nM homodi-
meric concentration) in HBS-P buffer (10 mM Hepes, 0.15 M
NaCl, 0.005% v/v Surfactant P20, pH 7.4) containing 1 mM
Ca
2+ and 10 mMZ n
2+. Regeneration of the surface between each
cycle was performed by injection of 30 mL HBS-P containing 3 M
EDTA.
EL4 lymphoma model and RT-PCR
C57BL/6, S100A9
2/2, TLR4
2/2 and RAGE
2/2 mice (12
weeks old) were injected subcutaneously with 50,000 EL4
lymphoma cells in 100 ml PBS. As control, 100 mL PBS alone
were injected. After 14 days the animals were scored for tumor
growth by palpation. All tumor positive animals were verified for
tumor growth by autopsy. In some experiments the tumors where
extracted and quantitated by weighting, while in others tumor
growth was measured with a microcaliper and tumor volume was
calculated every day, starting day 10 throughout the experiment,
as indicated. The tumor volume was calculated as volu-
me=L6W6W60.4, where L is the length (mm) and W (mm) is
the width of the tumor 6 [47].
Spleens were dissected and the cell suspension was thereafter
passed through a 70 mm cell strainer and cells washed in Hank’s
BSS (Invitrogen Life Technologies, Paisley, UK). Splenic CD11b
+
cells were purified using anti-CD11b magnetic beads and LS-
columns (Miltenyi Biotech, Bergisch Gladbach, Germany). Total
RNA was extracted from CD11b
+ cell preparations by use of the
Purelink RNA mini Kit (Invitrogen). RNA was reverse transcribed
to cDNA by use of the SuperScript III Platinum synthesis system
(Invitrogen). Real-time PCR (RT-PCR) was performed for the
detection of TGFb RNA and quantified using a SYBR GreenER
kit (Invitrogen) in a MYIQ (Bio-Rad) PCR machine. The
threshold cycle number was determined and relative expression
Figure 6. An S100A9-binding small molecule inhibits EL4 lymphoma growth in vivo. A. Binding of S100A9 to immobilized TLR4/MD2
complex is blocked by ABR-215050. Sensorgrams obtained after injection (2 min at 30 mL/min) of 50 nM S100A9 6 ABR-215050 over amine coupled
TLR4/MD2 (density ,2.3 kRU). Sensorgrams from top to bottom: S100A9 without competitor and with 3.91, 31.25 and 1,000 mM ABR-215050. Arrows
indicate injection of sample (1); sample buffer - i.e. HBS-P containing 1 mM Ca
2+ and 10 uM Zn
2+ (2); and regeneration of surface with 3 M EDTA (3). B.
Anti-tumor effect of ABR-215050 in EL4 tumors inoculated (s.c.) into wild type mice. The ABR-215050 was administrated in the drinking water at
30 mg/kg/day seven days/week from day 0 throughout the experiment. Each data point represents mean 6 SEM (n=10; p,0.01, Mann Whitney U).
Control animals received only normal drinking water. The water intake of the animals was not affected by the presence of ABR-215050 in the drinking
water. C. ELISA measurements of TGFb serum levels day 20 in C57BL/6 animals inoculated with EL4 tumors and animals treated with 30 mg/kg/day of
ABR-215050, as indicated (p=0.0037, Student t test).
doi:10.1371/journal.pone.0034207.g006
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(Rt– Et),
where Rt and Et are the threshold cycles for the reference gene (b-
actin) and the target gene, respectively. Where mean values from
several experiments are shown the expression in C57BL/6
controls have been set to 1.
TGFb ELISA
The TGFb1 Quantikine ELISA kit (Abnova Taipei, Taiwan)
was utilized to determine serum TGFb levels, as indicated. Serum
from individual animals in normal and EL-4 tumor bearing
animals and acid activated as per manufacturers direction.
Samples were diluted and assayed in as described by the
manufacturer. Prism 4 software was used to construct a TGFb
standard curve and subsequently to quantitate sample TGFb
concentrations. Cumulative TGFb levels over all time points were
graphed using Prism 4.
Statistical analysis
Statistical analysis was performed with Prism 4 software
(GraphPad Software, Inc.) using an unpaired two-tailed Student’s
t test or Gehan-Breslow-Wilcoxon test, as indicated. Error bars
represent SEM. Statistical differences for the mean values are
indicated as follows: *, P,0.05; **, P,0.01; ***, P,0.001.
Supporting Information
Figure S1 RT-PCR analysis of the indicated genes using RNA
from CD11b+ spleen cells, as described in Materials and Methods.
(TIF)
Figure S2 RNA from EL4 cells were analyzed with regard to
TGFb expression. CD3 expressing (MACS purification) cells from
collagenase treated tumors were used as a source for EL4 in vivo
RNA.
(TIF)
Figure S3 Upper panel: Recombinant S100A9 bind to amine
coupled ABR-215050 in the presence of 1 mM Ca
++ and 10 mM
Zn
++. Lower panel: ABR215050 inhibits the interaction between
S100A9 and RAGE. (curve was fit to a sigmoidal dose-response
model in GraphPad Prism).
(TIF)
Figure S4 Intra-cellular staining of S100A9 in spleens from
C57BL/6 and S100
2/2 mice. An affinity, purified rabbit anti-
mouse S100A9 antibody was used to detect S100A9 in
permeabilized cells.
(TIF)
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